Lilly, Novo's bet on heart disease starts to take shape, and 2024 could be a pivotal year for their GLP-1s - Endpoints News
- Lilly, Novo's bet on heart disease starts to take shape, and 2024 could be a pivotal year for their GLP-1s Endpoints News
- GLP-1 RAs for CVD: Are Cardiologists Ready? Medscape
- Semaglutide and Cardiovascular Outcomes in Obesity | NEJM nejm.org
- Wegovy found to reduce risk of serious heart problems | Health Smart WPMT FOX 43
- Targeting obesity may be 'highly effective strategy' for treating HFpEF, ASCVD Healio